[go: up one dir, main page]

WO2011070767A1 - Agent prophylactique pour la dermatite atopique - Google Patents

Agent prophylactique pour la dermatite atopique Download PDF

Info

Publication number
WO2011070767A1
WO2011070767A1 PCT/JP2010/007099 JP2010007099W WO2011070767A1 WO 2011070767 A1 WO2011070767 A1 WO 2011070767A1 JP 2010007099 W JP2010007099 W JP 2010007099W WO 2011070767 A1 WO2011070767 A1 WO 2011070767A1
Authority
WO
WIPO (PCT)
Prior art keywords
parts
weight
collagen
group
atopic dermatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2010/007099
Other languages
English (en)
Japanese (ja)
Inventor
裕明 樋口
成瀬　敦
大澤　謙二
和正 清水
雅範 伊藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lotte Co Ltd
Original Assignee
Lotte Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lotte Co Ltd filed Critical Lotte Co Ltd
Priority to CN2010800558465A priority Critical patent/CN102652021A/zh
Priority to JP2011545082A priority patent/JP5788332B2/ja
Priority to KR1020127017437A priority patent/KR20120123301A/ko
Priority to US13/514,975 priority patent/US20120253014A1/en
Publication of WO2011070767A1 publication Critical patent/WO2011070767A1/fr
Anticipated expiration legal-status Critical
Priority to US14/253,997 priority patent/US20140228297A1/en
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A23L2/66—Proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/275—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of animal origin, e.g. chitin
    • A23L29/281—Proteins, e.g. gelatin or collagen
    • A23L29/284—Gelatin; Collagen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to an atopic dermatitis preventive agent and a food containing the same.
  • Atopic dermatitis is a disease whose main lesion is hazy eczema that repeats exacerbations and remissions.
  • Major lesions of atopic dermatitis include erythema or papules on the skin, ear cuts, dry skin, pore-matched keratotic papules with wrinkled desquamation, and scratches on the affected skin.
  • the prevalence of atopic dermatitis was 12.8% for 4-month-old children, 9.8% for half-year-old children, 13.2% for 3-year-old children, 11.8% for first-year elementary school students, and 6th-grade elementary school students. It is 10.6%, and the first grader is 8.2%, which is as high as 1 in 10 children.
  • the main causes and exacerbations are food, sweating, environmental factors, bacterial fungi, contact antigens, stress, etc., and treatment and prevention are required.
  • Treatment of atopic dermatitis is carried out by 1) search for causes / aggravation factors and countermeasures 2) skin care 3) drug therapy. 1) If the symptoms are not resolved by 2), treatment with drugs is performed.
  • drugs steroid topical drugs are most widely used, and there are many types of steroid topical drugs.
  • protopic which is an immunomodulator, has recently been recognized as useful.
  • antihistamines and antiallergic drugs are used as oral drugs, and oral steroids may be temporarily used only for the most severe patients.
  • steroids may have side effects such as skin atrophy, vasodilatation, and keratitis.
  • topical steroids are used on the face. I am instructed not to use medicine as much as possible. Many patients with steroid drugs have a negative reaction because they are anxious about side effects. Protopic, on the other hand, is a relatively new drug that was approved for use in November 1999. It is still only approved for use at low concentrations in children, and it can also be used in children under 2 years of age. Not allowed. Antihistamines and antiallergic drugs, which are internal medicines, may cause side effects such as drowsiness, dullness, and difficulty in sputation of sputum associated with anticholinergic action.
  • Collagen is a major protein component that constitutes the connective tissue of animals, is a raw material for gelatin and glue, and has long been used as a food ingredient. Collagen is also routinely ingested from meat stew and has been widely confirmed to be safe. Collagen is a protein characterized by having a collagen triple helix structure, and more than 30 types have been reported, and they are called as type I and type II, respectively.
  • Type I collagen is the main component in dermis, ligaments, tendons, bones, etc.
  • type II collagen is the main component in articular cartilage.
  • type IV collagen is mainly contained in the basement membrane which is the lining structure of all epithelial tissues. The most abundant in the body is type I collagen.
  • Non-patent Document 1 It has been shown using a mouse atopic dermatitis model that application of marine collagen or oral administration suppresses atopic dermatitis after onset. However, there is no mention of prevention of atopic dermatitis before onset.
  • An object of the present invention is to provide an agent for preventing atopic dermatitis and a food containing the same.
  • the present invention provides an atopic dermatitis preventive agent comprising collagen and a food or drink containing the atopic dermatitis preventive agent.
  • Collagen has a high ratio of total protein in the living body of mammals and can be obtained at low cost.
  • Collagen is a raw material for gelatin and glue and has been used as a food for a long time. Furthermore, it is taken daily from meat stew, and its safety has been widely confirmed.
  • the origin of the collagen of the present invention is not particularly limited, and those derived from mammals such as cows and pigs, birds such as chickens and ostriches, fishes such as sharks, and the like can be used. Those derived from livestock such as cows, pigs and chickens are particularly preferred because they are easily available in large quantities.
  • the type of collagen is not particularly limited, and any type can be used, and a mixture of a plurality of types of collagen may be used.
  • the collagen may be collagen itself, gelatin, or a collagen peptide.
  • Gelatin refers to a product obtained by pretreating collagen with an acid or alkali, followed by thermal hydrolysis and solubilization.
  • Collagen peptide refers to low molecular collagen obtained by hydrolyzing collagen with acid, alkali, enzyme or the like.
  • a collagen hydrolyzate is obtained by immersing the skin and joints of animals such as pigs, cows and chickens, or the scales and skins of fish in an acid or alkaline solution, obtaining gelatin by extraction, and treating this with enzymes or acids. Can be obtained.
  • the atopic dermatitis preventive agent of the present invention is for oral use, but may be administered in any form, for example, in the form of tablets, capsules, drinks and the like.
  • the atopic dermatitis preventive agent of the present invention may be contained in food and drink, and in that case, the food and drink to be contained is not limited.
  • animals such as fresh food, meat and fish Foods, vegetable foods such as cereals, vegetables, processed foods such as dairy products, bread and instant foods, taste foods such as confectionery, cooking seasoning materials such as sweeteners and seasonings, health foods, special-purpose foods, It can be contained in beverages such as water, soft drinks, alcoholic beverages, tea, food processing materials, food additives and the like.
  • Collagen mixed feed is a control feed with 0.20% collagen peptide added. Collagen mixed feed is adjusted so that the daily intake of collagen is 200 mg / Kg.
  • porcine collagen peptide manufactured by Zerais Co., Ltd. was used as the collagen in the collagen mixed feed. Porcine collagen peptide is obtained by further enzymatically decomposing gelatin obtained by soaking pig skin in an acid or alkaline solution and extracting it. The collagen peptide is mainly derived from porcine type I collagen.
  • mice Seven and two 5-week-old NC / NgaTnd mice were prepared for each group. These were designated as a collagen administration group and a control feed administration group, respectively. Both were preliminarily fed for 1 week, and then freely fed with collagen-mixed feed or control feed and water for 6 weeks, respectively. None of the mice developed dermatitis at the start of feed administration. The following seven items were evaluated for each group during and after each feed administration period. The test period for each item is shown in parentheses.
  • Judgment of clinical symptom score (twice / week during feed administration period) (2) Measurement of curettage and duration (before and after feed administration period) (3) Measurement of total IgE level in blood (of feed administration period) Before and after) (4) Transepidermal water loss (TEWL) measurement (once during feed administration period / 2 weeks) (5) Body weight measurement (once during feed administration period / 2 weeks), (6) Macroscopic observation of skin lesions (At the end of the feed administration period) and (7) Histological examination (after the end of the feed administration period).
  • TEWL Transepidermal water loss
  • Test method for each evaluation item (1) Judgment of clinical symptom score Twice weekly from the start of feeding the test meal and from the start of feeding to the day after the last feeding, “pruritus symptom”, “erythema / bleeding”, “edema”, “scratch” / Erosion and desquamation / drying are judged in four stages: “0: None”, “1: Mild”, “2: Moderate”, and “3: Severe”. The total score is shown. It should be noted that the person to be judged and the person to be fed were conducted by different persons throughout the test period so that the judge did not know which group the animal belonged to.
  • the clinical symptom score at the start of feed administration was 0 (not developed).
  • the clinical symptom score gradually increased from 3 days after the start of the feed administration, and the clinical symptom score at the end of the feed administration period was 5.9 ⁇ 1.7.
  • the collagen administration group the dermatitis score increased in the same manner as in the control diet administration group until the 25th day after starting the feed administration, but the skin inflammatory condition did not show any significant deterioration after 25 days after the start of the feed administration.
  • the clinical symptom score after the end of the feed administration period maintained a mild state of 3.6 ⁇ 0.8.
  • the clinical symptom score tended to be lower than that in the control feed group.
  • Fig. 2 shows the number of scratching behaviors (30 minutes) before and after the feed administration period in each group. Data before the start of feed administration (day 0) and after the end of the feed administration period (day 43) were expressed as mean ⁇ standard error (7 animals per group).
  • FIG. 3 shows the scratching time (seconds / 30 minutes) before and after the feed administration period in each group. Data before the start of feed administration (day 0) and after the end of the feed administration period (day 43) were expressed as mean ⁇ standard error (7 animals per group).
  • the number of scratching behavior (Scratching Frequency) and scratching duration (seconds) before the start of feed administration (study day 0) were about 10 and 10 seconds, respectively, per 30-minute shooting time. It was. In both groups, the number of scratching behavior and the time of scratching behavior tended to increase after the end of the feed administration period (day 43) compared to before the start of feed administration, although there was no significant difference, but the number of scratching behavior and scratching were not observed. The value of the action time was lower in the collagen administration group than in the control diet administration group.
  • FIG. 4 shows the total IgE value in blood before and after the feed administration period in each group. Data before the start of feed administration (day 0) and after the end of the feed administration period (day 43) were expressed as mean ⁇ standard error (7 animals per group).
  • TEWL at the start of feed administration was 5 g / hr / m 2 or less, which was within the normal range. TEWL tends to increase after 15 days from the start of feed administration, especially in the control feed administration group, and rises with time, and at the end of the feed administration period (day 43) 25.97 ⁇ 3.85 g / hr / m A high value of 2 was shown. Although it also increased in the collagen administration group, the value was slightly low at the end of the feed administration period, which was 23.72 ⁇ 9.38 g / hr / m 2 , although no significant difference was observed.
  • FIG. 6 shows the transition of body weight in each group. Data before the start of feed administration (day 0), 15 days, 29 days, and after the end of the feed administration period (day 43) were expressed as mean ⁇ standard error (7 animals per group).
  • the body weight at the start of feed administration was 18.7 to 20.8 g. Thereafter, both groups increased over time, and there was no difference between the groups in the rate of increase.
  • FIG. 7 shows macroscopic findings in each group. These macro photographs were taken before sampling of the histological examination of (7) for each group of mice after the end of the feed administration period.
  • B Collagen
  • D Control diet
  • FIG. 8 shows the number of eosinophils and the number of mast cells in the dorsal skin tissue in each group.
  • the results of counting the skin tissues collected after the end of the feed administration period (day 43) are shown as the mean value ⁇ standard error (7 animals per group).
  • the number of cells was small in both the number of eosinophils and the number of mast cells, although no significant difference was observed compared to the control feed group.
  • Example 1 Summary of Example 1 In both groups, no dermatitis was observed in any test at the start of feed administration. In either group, dermatitis develops afterwards, but in NC / NgaTnd mice administered with collagen diet, clinical symptom score, number of curettages and duration, total IgE level in blood, TEWL, macroscopic lesion In observation and histological examination, a decrease in value was observed compared to the control group. From the above, it was shown that there is an effect of preventing atopic dermatitis by administering collagen before onset.
  • Beverages, powders, tablets, chewing gums, candy, and tablet confections were manufactured according to the following prescription.
  • beverage Collagen peptide 5.0 parts by weight Fructose glucose liquid sugar 8.0 parts by weight Sugar 4.0 parts by weight Fragrance 0.5 parts by weight Vitamin C 5.0 parts by weight After adjusting to pH 3.8, 100 parts by volume with purified water.
  • beverage Collagen peptide 5.0 parts by weight Sucralose 0.005 parts by weight Stevioside 0.008 parts by weight Rebaudioside 0.008 parts by weight Acesulfame potassium 0.01 parts by weight Peach flavor 0.5 parts by weight Vitamin C 0.5 After adjusting the pH to 3.8 using parts by weight of acidulant, it was adjusted to 100 parts by volume with purified water.
  • beverage Collagen peptide 5.0 parts by weight Acidic dairy drink 5.0 parts by weight Fructose glucose liquid sugar 10.0 parts by weight Fragrance 0.5 parts by weight Vitamin C 5.0 parts by weight Adjusted to pH 3.8 After that, it was made up to 100 parts by volume with purified water.
  • Prescription collagen peptide of jelly beverage 5.0 parts by weight fructose glucose liquid sugar 8.0 parts by weight sugar 4.0 parts by weight perfume 0.5 parts by weight vitamin C 5.0 parts by weight Gelling stabilizer 0.5 parts by weight acidity After adjusting the pH to 3.8 using a sample, the volume was adjusted to 100 parts by volume with purified water.
  • Coffee beverage Collagen peptide 5.0 parts by weight Coffee extract 5.0 parts by weight Sugar 4.0 parts by weight Fragrance 0.5 parts by weight Vitamin C 0.5 parts by weight Baking soda is used to adjust to pH 6.5, and then purified water 100 parts by volume.
  • Prescription Collagen Peptide of Green Tea Beverage 5.0 parts by weight Green Tea Extract 10.0 parts by weight Fragrance 0.5 parts by weight Vitamin C 0.5 parts by weight Baking soda is used to adjust the pH to 6.5, and then 100 parts by volume with purified water. did.
  • Chewing gum prescription collagen peptide 5.0 parts by weight gum base 20.0 parts by weight sugar 55.0 parts by weight glucose 10.5 parts by weight starch syrup 9.0 parts by weight fragrance 0.5 parts by weight
  • Prescription collagen peptide 5.0 parts by weight Sugar 73.5 parts by weight Glucose 17.0 parts by weight Sucrose fatty acid ester 0.2 parts by weight Fragrance 0.2 parts by weight Water 4.1 parts by weight
  • Gummy jelly prescription collagen peptide 5.0 parts by weight gelatin 55.0 parts by weight starch syrup 23.0 parts by weight sugar 8.5 parts by weight vegetable oil 4.5 parts by weight mannitol 3.0 parts by weight lemon juice 1.0 part by weight
  • Prescription collagen peptide 5.0 parts by weight Powdered sugar 36.8 parts by weight Cocoa bitter 20.0 parts by weight Whole milk powder 20.0 parts by weight Cocoa butter 17.0 parts by weight Mannitol 1.0 parts by weight Fragrance 0.2 weight Part
  • Sherbet prescription collagen peptide 5.0 parts by weight Orange fruit juice 25.0 parts by weight Sugar 23.0 parts by weight Egg white 9.0 parts by weight Water 38.0 parts by weight

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fodder In General (AREA)

Abstract

La présente invention a pour objet : un agent prophylactique pour la dermatite atopique ; et un aliment contenant l'agent prophylactique. Des études approfondies ont été réalisées, et il a été découvert que la dermatite atopique peut être prévenue par l'ingestion orale de collagène. La présente invention concerne spécifiquement : un agent prophylactique pour la dermatite atopique, qui comprend du collagène ; et un aliment ou une boisson contenant l'agent prophylactique pour la dermatite atopique.
PCT/JP2010/007099 2009-12-10 2010-12-07 Agent prophylactique pour la dermatite atopique Ceased WO2011070767A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN2010800558465A CN102652021A (zh) 2009-12-10 2010-12-07 特应性皮炎预防剂
JP2011545082A JP5788332B2 (ja) 2009-12-10 2010-12-07 アトピー性皮膚炎予防剤
KR1020127017437A KR20120123301A (ko) 2009-12-10 2010-12-07 아토피성 피부염 예방제
US13/514,975 US20120253014A1 (en) 2009-12-10 2010-12-07 Preventive agent for atopic dermatitis
US14/253,997 US20140228297A1 (en) 2009-12-10 2014-04-16 Preventive agent for atopic dermatitis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009-280606 2009-12-10
JP2009280606 2009-12-10

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/514,975 A-371-Of-International US20120253014A1 (en) 2009-12-10 2010-12-07 Preventive agent for atopic dermatitis
US14/253,997 Division US20140228297A1 (en) 2009-12-10 2014-04-16 Preventive agent for atopic dermatitis

Publications (1)

Publication Number Publication Date
WO2011070767A1 true WO2011070767A1 (fr) 2011-06-16

Family

ID=44145329

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/007099 Ceased WO2011070767A1 (fr) 2009-12-10 2010-12-07 Agent prophylactique pour la dermatite atopique

Country Status (6)

Country Link
US (2) US20120253014A1 (fr)
JP (1) JP5788332B2 (fr)
KR (1) KR20120123301A (fr)
CN (1) CN102652021A (fr)
TW (1) TW201143634A (fr)
WO (1) WO2011070767A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013049540A3 (fr) * 2011-09-30 2013-06-27 Pepsico, Inc. Boissons de nutrition
WO2014175001A1 (fr) * 2013-04-26 2014-10-30 新田ゼラチン株式会社 Agent favorisant le blanchiment ou agent améliorant la dermite atopique
JP2015126699A (ja) * 2013-12-27 2015-07-09 丸善製薬株式会社 飲料組成物の品質安定化方法および飲料組成物
JP2022515392A (ja) * 2018-12-21 2022-02-18 ゲリタ アクチェンゲゼルシャフト 皮膚障害及び腸障害で使用するためのコラーゲン加水分解物
JP2023515867A (ja) * 2020-03-03 2023-04-14 ロンザ・グリーンウッド・エルエルシー 食品および飲料用途での非変性ｉｉ型コラーゲンならびにその使用
JP7516585B1 (ja) 2023-01-24 2024-07-16 イノ－アイティー・カンパニー・リミテッド 電気加熱式喫煙物品内に挿入可能なゲル収容体ロッド、これを含む電気加熱式喫煙物品及びこのためのエアロゾル発生装置

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014114939A1 (fr) 2013-01-23 2014-07-31 Bottled Science Limited Composition de boisson améliorant la peau
RU2014113053A (ru) * 2014-03-29 2015-10-10 Дзе Консентрейт Мэньюфекчуринг Компани Оф Айрлэнд Питательные напитки

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004039368A1 (fr) * 2002-11-01 2004-05-13 Kyowa Hakko Kogyo Co., Ltd. Preparation perorale pour la prevention ou le traitement de la dermatite atopique
JP2007167079A (ja) * 2007-03-30 2007-07-05 Sanei Gen Ffi Inc コラーゲン含有酸性飲食品
JP2008072935A (ja) * 2006-09-20 2008-04-03 Saitou Shoji:Kk 豆腐を含有するドレッシング
JP2008148610A (ja) * 2006-12-15 2008-07-03 Nisshin Oillio Group Ltd コラーゲン含有食品

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5645851A (en) * 1994-02-28 1997-07-08 Moore; Eugene R. Product for alleviating the symptons of arthritis in mammals
US6919306B2 (en) * 1999-08-09 2005-07-19 Yaizu Suisankagaku Industry Co. Ltd. Method of skin care
JP4249853B2 (ja) * 1999-08-09 2009-04-08 焼津水産化学工業株式会社 経口用皮膚潤い改善剤
JP2001302690A (ja) * 2000-04-19 2001-10-31 Miyagi Kagaku Kogyo Kk 皮膚浸透性トリペプチド、皮膚浸透性コラーゲンペプチド、皮膚浸透性外用剤および高吸収性食品
CN101340905B (zh) * 2005-12-05 2012-05-16 协和发酵生化株式会社 用于防止或改善皮肤干燥的口服制剂
JP5336048B2 (ja) * 2007-02-14 2013-11-06 新垣 裕子 鶏由来コラーゲン高含有物およびその抽出方法
WO2009128584A1 (fr) * 2008-04-14 2009-10-22 C.A. Pharm Co., Ltd. Composition pour la prévention et le traitement de vergetures et d'une atopie

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004039368A1 (fr) * 2002-11-01 2004-05-13 Kyowa Hakko Kogyo Co., Ltd. Preparation perorale pour la prevention ou le traitement de la dermatite atopique
JP2008072935A (ja) * 2006-09-20 2008-04-03 Saitou Shoji:Kk 豆腐を含有するドレッシング
JP2008148610A (ja) * 2006-12-15 2008-07-03 Nisshin Oillio Group Ltd コラーゲン含有食品
JP2007167079A (ja) * 2007-03-30 2007-07-05 Sanei Gen Ffi Inc コラーゲン含有酸性飲食品

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHISAKO HAYAMI: "Barrier functions of atopic dermatitis", IGAKU NO AYUMI, vol. 228, no. L, 3 January 2009 (2009-01-03), pages 15 - 19 *
HIROKI OHARA ET AL.: "Improvement in the Moisture Content of the Stratum Corneum Following 4 Weeks of Collagen Hydrolysate Ingestion", JOURNAL OF THE JAPANESE SOCIETY FOR FOOD SCIENCE AND TECHNOLOGY, vol. 56, no. 3, March 2009 (2009-03-01), pages 137 - 145 *
MICHIKO SAITO ET AL.: "Kaiyosei Collagen Peptide 'Marine Matrix' no Tokusei to Biyo Koka", FOOD STYLE 21, vol. 7, no. 2, 1 February 2003 (2003-02-01), pages 85 - 88 *
OHARA, H. ET AL.: "Comparison of quantity and structures of hydroxyproline-containing peptides in human blood after oral ingestion of gelatin hydrolysates from different sources", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 55, no. 4, 2007, pages 1532 - 1535 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013049540A3 (fr) * 2011-09-30 2013-06-27 Pepsico, Inc. Boissons de nutrition
EP2760296A2 (fr) * 2011-09-30 2014-08-06 The Concentrate Manufacturing Company of Ireland Boissons de nutrition
WO2014175001A1 (fr) * 2013-04-26 2014-10-30 新田ゼラチン株式会社 Agent favorisant le blanchiment ou agent améliorant la dermite atopique
JPWO2014175001A1 (ja) * 2013-04-26 2017-02-23 新田ゼラチン株式会社 美白促進剤またはアトピー性皮膚炎改善剤
JP2015126699A (ja) * 2013-12-27 2015-07-09 丸善製薬株式会社 飲料組成物の品質安定化方法および飲料組成物
JP2022515392A (ja) * 2018-12-21 2022-02-18 ゲリタ アクチェンゲゼルシャフト 皮膚障害及び腸障害で使用するためのコラーゲン加水分解物
JP7717609B2 (ja) 2018-12-21 2025-08-04 ゲリタ アクチェンゲゼルシャフト 皮膚障害及び腸障害で使用するためのコラーゲン加水分解物
JP2023515867A (ja) * 2020-03-03 2023-04-14 ロンザ・グリーンウッド・エルエルシー 食品および飲料用途での非変性ｉｉ型コラーゲンならびにその使用
JP7516585B1 (ja) 2023-01-24 2024-07-16 イノ－アイティー・カンパニー・リミテッド 電気加熱式喫煙物品内に挿入可能なゲル収容体ロッド、これを含む電気加熱式喫煙物品及びこのためのエアロゾル発生装置
JP2024104440A (ja) * 2023-01-24 2024-08-05 イノ－アイティー・カンパニー・リミテッド 電気加熱式喫煙物品内に挿入可能なゲル収容体ロッド、これを含む電気加熱式喫煙物品及びこのためのエアロゾル発生装置

Also Published As

Publication number Publication date
US20140228297A1 (en) 2014-08-14
JPWO2011070767A1 (ja) 2013-04-22
KR20120123301A (ko) 2012-11-08
CN102652021A (zh) 2012-08-29
JP5788332B2 (ja) 2015-09-30
US20120253014A1 (en) 2012-10-04
TW201143634A (en) 2011-12-16

Similar Documents

Publication Publication Date Title
JP5788332B2 (ja) アトピー性皮膚炎予防剤
CN103476421B (zh) 组合物、糖代谢改善剂以及糖代谢改善方法
US8722614B2 (en) Adiponectin production enhancer
TW201826948A (zh) 膳食益生增補品及其相關方法
CN101043896A (zh) 衍生自栗子的糖酶抑制剂及其应用
US20160303191A1 (en) Composition for preventing or treating osteoarthritis
JPWO2009142320A1 (ja) アトピー性皮膚炎予防剤及び／または治療剤
WO2011080887A1 (fr) Composition bloquant la sécrétion de sébum, et aliment ou boisson contenant cette composition
JP6629024B2 (ja) プロテオグリカンを含有する魚類軟骨水抽出物を含む経口組成物
JP2006104181A (ja) ブナ科植物由来の糖質分解酵素阻害物質、及びその用途
JP2010053120A (ja) 経口用肌改善剤、これを含有する食品、ならびに肌を改善する方法
JP2009084191A (ja) 食欲抑制用薬理組成物
JP2018070569A (ja) 肝星細胞の活性化抑制剤及び肝星細胞の活性化抑制用食品組成物
JP2023006159A (ja) 筋損傷回復促進剤、筋損傷に伴う炎症抑制剤及び筋損傷回復促進用経口組成物
JP6964960B2 (ja) 術後の創傷部及び／又は吻合部の回復を促進するための栄養組成物
TWI832945B (zh) 血糖值上昇抑制用、血中三酸甘油酯上昇抑制用組成物
KR20130132167A (ko) 프로타민 및 키토올리고당을 포함하는 비만의 예방 또는 치료용 조성물
TWI714413B (zh) 以含有硫酸軟骨素的豬軟骨萃取物作為有效成分的血壓上升抑制劑及含有其的食品組成物
US20040047895A1 (en) Laver protein-containing composition and foods
HK1175401A (en) Prophylactic agent for atopic dermatitis
JP4717413B2 (ja) 脂質代謝改善用組成物
JP2025075148A (ja) アディポネクチン増強剤、アディポネクチン増強用経口組成物及びプラズマローゲンの使用
JP2023175314A (ja) 便通改善用組成物及び機能性表示食品
JP3088111B2 (ja) サポニン含有アルコール吸収抑制剤
CN110139567A (zh) 用于胃肠炎症的膳食补充剂及其制备方法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080055846.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10835693

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2011545082

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 13514975

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20127017437

Country of ref document: KR

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 10835693

Country of ref document: EP

Kind code of ref document: A1